Short-course, high-dose beta-lactam therapy versus conventional dose and duration in critically ill patients: the HIT-HARD trial protocol for a phase III multicenter, cluster randomized, cross-over, non-inferiority trial
Abstract Background In critically ill patients with severe infections, beta-lactam antibiotics are frequently underdosed, while studies indicate that shorter treatment durations may be sufficient when adequately dosed. The HIT-HARD trial aims to evaluate whether short-course, high-dose beta-lactam therapy is non-inferior to conventional dosing and duration in critically ill patients with severe infections. A shorter course may reduce the development of antimicrobial resistance and serve a public health benefit. Methods The HIT-HARD trial (EU ref. 2024-514730-21-00) is a prospective, multicenter, cluster-randomized, cross-over, non-inferiority trial conducted in 14 hospitals (7 in Belgium and 7 in the Netherlands). The study aims to enroll 1,282 patients with organ dysfunction due to common infections (community-acquired pneumonia, hospital-acquired pneumonia, ventilator-associated pneumonia, intra-abdominal infection, or bloodstream infection). Patients treated with ceftriaxone, cefuroxime, cefotaxime, piperacillin–tazobactam, or meropenem can be included in the study. Exclusion criteria include prior study-antimicrobial therapy > 12 h for the current infection, absence of adequate source control, and infections requiring prolonged or specific dosing regimens. Participants are allocated to either the HIT-HARD strategy, a high-dose regimen (around 150–200% of standard dosing) for a short course of 3–5 days (72–120 h), or the CONTROL strategy, a conventional dosing regimen for 6–9 days (144–216 h). The primary endpoint is all-cause 90-day mortality. Secondary endpoints include mortality, recurrence of infection, antimicrobial resistance development, toxicity, antimicrobial exposure, clinical cure, resource utilization, health-related quality of life, and cost-effectiveness. Non-inferiority will be assessed using a pre-specified 7% margin by estimating the risk difference between the HIT-HARD and CONTROL groups with an unweighted cluster-level summary regression. Discussion By determining whether this short-course, high-dose approach is non-inferior to conventional regimens, the trial has the potential to directly inform antibiotic policy and guide an evidence-based approach to safely shorten antimicrobial therapy as part of an ICU stewardship program. Trial registration 20245147302100 (EUCT), prospective trial registration date 05DEC2024. Protocol version 3.0, protocol date 01JUN2026.
Authors
- Nynke G L Jager (ORCID: https://orcid.org/0000-0002-4524-9892)
- Jan J. De Waele (ORCID: https://orcid.org/0000-0003-1017-9748)
- Jeroen A. Schouten (ORCID: https://orcid.org/0000-0001-9118-4420)
- Leanne J. Kosse (ORCID: https://orcid.org/0000-0002-9358-2286)
- Steven Teerenstra (ORCID: https://orcid.org/0000-0003-4103-7451)
- Liesbet De Bus (ORCID: https://orcid.org/0000-0003-1456-5857)
- Wietske Kievit (ORCID: https://orcid.org/0000-0002-3984-1769)
- Roger J. M. Brüggemann (ORCID: https://orcid.org/0000-0002-7618-725X)
- Jaap ten Oever (ORCID: https://orcid.org/0000-0003-2397-0125)
- Maya Hites (ORCID: https://orcid.org/0000-0001-6961-6039)
- Nicolas De Schryver (ORCID: https://orcid.org/0000-0003-4584-0903)
- Jerina Boelens (ORCID: https://orcid.org/0000-0003-2282-8194)
- Isabel Spriet (ORCID: https://orcid.org/0000-0001-6342-0676)
- Charlotte H. S. B. van den Berg (ORCID: https://orcid.org/0009-0009-8969-1509)
- M. Demaria (ORCID: https://orcid.org/0009-0007-3565-4118)
- D. Vermeiren
- On behalf of the HIT-HARD investigators
Institutions
- Université Libre de Bruxelles (BE)
- University Medical Center Groningen (NL)
- Radboud University Nijmegen (NL)
- University of Groningen (NL)
- Ghent University Hospital (BE)
- Radboud University Medical Center (NL)
- Ghent University (BE)
- Clinique Saint Pierre (BE)
- Radboud Institute for Health Sciences (NL)
- KU Leuven (BE)
Publication Details
- Journal
- BMC Infectious Diseases
- Published
- 2026-11-12
- DOI
- https://doi.org/10.1186/s12879-026-14707-3
- Primary Topic
- Antibiotics Pharmacokinetics and Efficacy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- ZonMw
- Belgian Health Care Knowledge Centre